Radiolabeled albumin through SNAr of cysteines as a potential pretargeting theranostic agent

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Radiolabeled albumin through SNAr of cysteines as a potential pretargeting theranostic agent. / Fischer, Niklas H.; van den Broek, Sara I. Lopes I.; Herth, Matthias M.; Diness, Frederik.

In: RSC Advances, Vol. 12, No. 54, 2022, p. 35032-35036.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Fischer, NH, van den Broek, SILI, Herth, MM & Diness, F 2022, 'Radiolabeled albumin through SNAr of cysteines as a potential pretargeting theranostic agent', RSC Advances, vol. 12, no. 54, pp. 35032-35036. https://doi.org/10.1039/d2ra06406e

APA

Fischer, N. H., van den Broek, S. I. L. I., Herth, M. M., & Diness, F. (2022). Radiolabeled albumin through SNAr of cysteines as a potential pretargeting theranostic agent. RSC Advances, 12(54), 35032-35036. https://doi.org/10.1039/d2ra06406e

Vancouver

Fischer NH, van den Broek SILI, Herth MM, Diness F. Radiolabeled albumin through SNAr of cysteines as a potential pretargeting theranostic agent. RSC Advances. 2022;12(54):35032-35036. https://doi.org/10.1039/d2ra06406e

Author

Fischer, Niklas H. ; van den Broek, Sara I. Lopes I. ; Herth, Matthias M. ; Diness, Frederik. / Radiolabeled albumin through SNAr of cysteines as a potential pretargeting theranostic agent. In: RSC Advances. 2022 ; Vol. 12, No. 54. pp. 35032-35036.

Bibtex

@article{abdd5deb76a74ae19b7fd830008df20b,
title = "Radiolabeled albumin through SNAr of cysteines as a potential pretargeting theranostic agent",
abstract = "Human serum albumin (HSA) has been shown to be a promising tumor targeting vector and target for generating theranostics by bioconjugation. Unstable chemical conjugation to HSA via a cysteine (Cys34) by reversible Michael additions is most commonly applied for this purpose. Herein, we describe utilization of our recently developed site-selective irreversible SNAr conjugation to Cys34 using perfluorobenzene sulfonyl derivatives to introduce a trans-cyclooctene (TCO) handle. The TCO could then be bioorthogonally ligated within minutes through an inverse-electron demand Diels-Alder reaction (IEDDA) to tetrazines (Tzs) containing a radionuclide. The methodology opens up a wide range of chemistries including pretargeting, 'click-to-release' tumor selective drug delivery or ultra-fast and complete conjugation of any drug. The proof-of-principle study demonstrated that the conjugation chemistry is feasible, robust and easy to carry out, being promising for pretargeted imaging and therapy studies as well as selective drug delivery using HSA.",
keywords = "SERUM-ALBUMIN, TETRAZINE, CYCLOADDITIONS, MECHANISMS, LIGATION",
author = "Fischer, {Niklas H.} and {van den Broek}, {Sara I. Lopes I.} and Herth, {Matthias M.} and Frederik Diness",
year = "2022",
doi = "10.1039/d2ra06406e",
language = "English",
volume = "12",
pages = "35032--35036",
journal = "RSC Advances",
issn = "2046-2069",
publisher = "RSC Publishing",
number = "54",

}

RIS

TY - JOUR

T1 - Radiolabeled albumin through SNAr of cysteines as a potential pretargeting theranostic agent

AU - Fischer, Niklas H.

AU - van den Broek, Sara I. Lopes I.

AU - Herth, Matthias M.

AU - Diness, Frederik

PY - 2022

Y1 - 2022

N2 - Human serum albumin (HSA) has been shown to be a promising tumor targeting vector and target for generating theranostics by bioconjugation. Unstable chemical conjugation to HSA via a cysteine (Cys34) by reversible Michael additions is most commonly applied for this purpose. Herein, we describe utilization of our recently developed site-selective irreversible SNAr conjugation to Cys34 using perfluorobenzene sulfonyl derivatives to introduce a trans-cyclooctene (TCO) handle. The TCO could then be bioorthogonally ligated within minutes through an inverse-electron demand Diels-Alder reaction (IEDDA) to tetrazines (Tzs) containing a radionuclide. The methodology opens up a wide range of chemistries including pretargeting, 'click-to-release' tumor selective drug delivery or ultra-fast and complete conjugation of any drug. The proof-of-principle study demonstrated that the conjugation chemistry is feasible, robust and easy to carry out, being promising for pretargeted imaging and therapy studies as well as selective drug delivery using HSA.

AB - Human serum albumin (HSA) has been shown to be a promising tumor targeting vector and target for generating theranostics by bioconjugation. Unstable chemical conjugation to HSA via a cysteine (Cys34) by reversible Michael additions is most commonly applied for this purpose. Herein, we describe utilization of our recently developed site-selective irreversible SNAr conjugation to Cys34 using perfluorobenzene sulfonyl derivatives to introduce a trans-cyclooctene (TCO) handle. The TCO could then be bioorthogonally ligated within minutes through an inverse-electron demand Diels-Alder reaction (IEDDA) to tetrazines (Tzs) containing a radionuclide. The methodology opens up a wide range of chemistries including pretargeting, 'click-to-release' tumor selective drug delivery or ultra-fast and complete conjugation of any drug. The proof-of-principle study demonstrated that the conjugation chemistry is feasible, robust and easy to carry out, being promising for pretargeted imaging and therapy studies as well as selective drug delivery using HSA.

KW - SERUM-ALBUMIN

KW - TETRAZINE

KW - CYCLOADDITIONS

KW - MECHANISMS

KW - LIGATION

U2 - 10.1039/d2ra06406e

DO - 10.1039/d2ra06406e

M3 - Journal article

C2 - 36540259

VL - 12

SP - 35032

EP - 35036

JO - RSC Advances

JF - RSC Advances

SN - 2046-2069

IS - 54

ER -

ID: 329206207